{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:28:18Z","timestamp":1790162898494,"version":"4.1.0"},"reference-count":67,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cushing syndrome (CS) is a clinical condition caused by increased plasma cortisol levels and characterized by high cardiovascular mortality. Among the metabolic effects of CS and its treatment, glycemic disturbances have been investigated in depth, while data on dyslipidemia is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Our study aims at evaluating the effects of CS treatment on serum lipid levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed, Scopus, and EMBASE databases to investigate the effects of CS treatment on serum total cholesterol (TC), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. Before-after analysis and subgroup analysis were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine observational or interventional studies (51.7% of good quality) were included in the quantitative analysis. Treatment of CS led to clinically and statistically significant decrease in serum TC (mean difference [MD] \u221226.49; 95% CI, \u221229.95 to \u221223.04; P &amp;lt; .00001), low-density lipoprotein cholesterol (MD \u221218.44; 95% CI, \u221221.30 to \u221215.57; P &amp;lt; .00001), and triglycerides levels (MD \u221217.77; 95% CI, \u221222.70 to \u221212.84; P &amp;lt; .00001), with no significant changes in high-density lipoprotein cholesterol levels (MD \u22122.34; 95% CI, \u22126.96 to 2.28; P = .32). Subgroup analysis showed greater decrease in TC levels in subjects with adrenal hypercortisolism, in those treated with steroidogenesis inhibitors, and in those with treatment duration \u226512 months. In addition, CS treatment significantly decreased blood glucose levels, body mass index, waist circumference, and insulin resistance index.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates a significant improvement in serum lipid levels after treatment of CS. Because the cardiovascular complications of hypercortisolism depend on several factors, further studies are needed to determine whether this directly translates into an adequate reduction in the risk of major cardiovascular events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf681","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:36:50Z","timestamp":1766407010000},"page":"1187-1202","source":"Crossref","is-referenced-by-count":2,"title":["The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9290-5699","authenticated-orcid":false,"given":"Gianmaria","family":"Salvio","sequence":"first","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ciarloni","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairus","family":"Aboud","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ambo","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Bordoni","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Lucchetti","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Martino","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Perrone","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Gasparroni","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Balercia","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche , Ancona 60126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6204-3423","authenticated-orcid":false,"given":"Giorgio","family":"Arnaldi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, PROMISE, University of Palermo , Palermo 90127 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"8","key":"2026031619574779200_dgaf681-B1","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026031619574779200_dgaf681-B2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl. 1","key":"2026031619574779200_dgaf681-B3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing's syndrome","volume":"92","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"4","key":"2026031619574779200_dgaf681-B4","doi-asserted-by":"crossref","first-page":"M133","DOI":"10.1530\/EJE-15-0354","article-title":"Metabolic comorbidities in Cushing's syndrome","volume":"173","author":"Ferra\u00f9","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026031619574779200_dgaf681-B5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","article-title":"Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission: Cushing's syndrome and metabolic\/cardiovascular outcomes","volume":"75","author":"Giordano","year":"2011","journal-title":"Clin Endocrinol"},{"issue":"7","key":"2026031619574779200_dgaf681-B6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026031619574779200_dgaf681-B7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1530\/EJE-13-0569","article-title":"Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up","volume":"169","author":"Ntali","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026031619574779200_dgaf681-B8","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1210\/clinem\/dgaa774","article-title":"Diabetes, active disease, and afternoon serum cortisol levels predict Cushing's disease mortality: a cohort study","volume":"106","author":"Rold\u00e1n-Sarmiento","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026031619574779200_dgaf681-B9","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality","volume":"106","author":"Schernthaner-Reiter","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026031619574779200_dgaf681-B10","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1210\/jc.2009-0290","article-title":"Hypercoagulable state in Cushing's syndrome: a systematic review","volume":"94","author":"Van Zaane","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026031619574779200_dgaf681-B11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2265.2003.01881.x","article-title":"Management of adrenocortical carcinoma","volume":"60","author":"Allolio","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026031619574779200_dgaf681-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-2275(20)38566-7","article-title":"Cholesterol metabolism during ketoconazole treatment in man","volume":"29","author":"Miettinen","year":"1988","journal-title":"J Lipid Res"},{"key":"2026031619574779200_dgaf681-B13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026031619574779200_dgaf681-B14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/9781119536604.ch6","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019","edition":"2nd ed"},{"key":"2026031619574779200_dgaf681-B15","author":"Wells","year":"2000"},{"issue":"9","key":"2026031619574779200_dgaf681-B16","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"3","key":"2026031619574779200_dgaf681-B17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1507\/endocrj.K09E-260","article-title":"Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushing's syndrome","volume":"57","author":"Akaza","year":"2010","journal-title":"Endocr J"},{"issue":"1","key":"2026031619574779200_dgaf681-B18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","article-title":"Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study","volume":"61","author":"Albani","year":"2018","journal-title":"Endocrine"},{"issue":"12","key":"2026031619574779200_dgaf681-B19","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1210\/jc.2015-2662","article-title":"Unilateral adrenalectomy as a first-line treatment of Cushing's syndrome in patients with primary bilateral macronodular adrenal hyperplasia","volume":"100","author":"Debillon","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026031619574779200_dgaf681-B20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/a-0879-5122","article-title":"Pattern of lipid abnormalities among south Asian Indians with Cushing's syndrome and the short term impact of surgical correction of hypercortisolism","volume":"51","author":"Dhingra","year":"2019","journal-title":"Horm Metab Res"},{"issue":"9","key":"2026031619574779200_dgaf681-B21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00268-005-0681-x","article-title":"Evaluation of the cardiovascular risk in patients with subclinical cushing syndrome before and after surgery","volume":"30","author":"Erbil","year":"2006","journal-title":"World J Surg"},{"issue":"6","key":"2026031619574779200_dgaf681-B22","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2002-021558","article-title":"Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026031619574779200_dgaf681-B23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"5","key":"2026031619574779200_dgaf681-B24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jc.2011-3123","article-title":"Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI","volume":"97","author":"Geer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026031619574779200_dgaf681-B25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12020-017-1276-7","article-title":"Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing's disease","volume":"59","author":"Guarnotta","year":"2018","journal-title":"Endocrine"},{"issue":"3","key":"2026031619574779200_dgaf681-B26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40618-023-02183-4","article-title":"Cardiovascular evaluation and endothelial dysfunction in Cushing syndrome following remission: a prospective study","volume":"47","author":"Hacioglu","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026031619574779200_dgaf681-B27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2265.2004.02169.x","article-title":"Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery","volume":"62","author":"Lib\u00e8","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026031619574779200_dgaf681-B28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41390-019-0438-0","article-title":"Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks","volume":"86","author":"Makri","year":"2019","journal-title":"Pediatr Res"},{"key":"2026031619574779200_dgaf681-B29","doi-asserted-by":"crossref","first-page":"595894","DOI":"10.3389\/fendo.2021.595894","article-title":"Levoketoconazole in the treatment of patients with Cushing's syndrome and diabetes mellitus: results from the SONICS phase 3 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front. Endocrinol"},{"issue":"3","key":"2026031619574779200_dgaf681-B30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","article-title":"The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on \u201creal-world evidence.\u201d","volume":"64","author":"Pivonello","year":"2019","journal-title":"Endocrine"},{"issue":"1","key":"2026031619574779200_dgaf681-B31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40618-019-01077-8","article-title":"The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center","volume":"43","author":"Simeoli","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"2026031619574779200_dgaf681-B32","doi-asserted-by":"crossref","first-page":"600323","DOI":"10.3389\/fendo.2020.600323","article-title":"Lipid abnormalities in patients with Cushing's disease and its relationship with impaired glucose metabolism","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Endocrinol"},{"issue":"3","key":"2026031619574779200_dgaf681-B33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1210\/jcem-57-3-619","article-title":"Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome","volume":"57","author":"Taskinen","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026031619574779200_dgaf681-B34","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.21037\/gs-24-398","article-title":"Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study","volume":"13","author":"Wonglhaw","year":"2024","journal-title":"Gland Surg"},{"issue":"10","key":"2026031619574779200_dgaf681-B35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2026031619574779200_dgaf681-B36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a phase III trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"2026031619574779200_dgaf681-B37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026031619574779200_dgaf681-B38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","article-title":"Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial","volume":"18","author":"Schopohl","year":"2015","journal-title":"Pituitary"},{"issue":"11","key":"2026031619574779200_dgaf681-B39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","article-title":"Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study","volume":"43","author":"Lacroix","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2026031619574779200_dgaf681-B40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2026031619574779200_dgaf681-B41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2026031619574779200_dgaf681-B42","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026031619574779200_dgaf681-B43","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2026031619574779200_dgaf681-B44","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031619574779200_dgaf681-B45","doi-asserted-by":"crossref","unstructured":"Salvio G, Ciarloni A, Aboud N, et al \u00a02025. Supplemental material for the effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis. Figshare. 10.6084\/m9.figshare.30760781.","DOI":"10.1210\/clinem\/dgaf681"},{"issue":"4","key":"2026031619574779200_dgaf681-B46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ejendo\/lvaf059","article-title":"Mortality in Cushing's syndrome: declining over two decades but remaining higher than the general population","volume":"192","author":"Akirov","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026031619574779200_dgaf681-B47","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11102-022-01258-4","article-title":"Cardiovascular health and mortality in Cushing's disease","volume":"25","author":"Coulden","year":"2022","journal-title":"Pituitary"},{"issue":"8","key":"2026031619574779200_dgaf681-B48","doi-asserted-by":"crossref","first-page":"e13143","DOI":"10.1111\/jne.13143","article-title":"Glucose and lipid metabolism abnormalities in Cushing's syndrome","volume":"34","author":"Salehidoost","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"1","key":"2026031619574779200_dgaf681-B49","first-page":"36","article-title":"Metabolic profile differences in ACTH-dependent and ACTH-independent Cushing syndrome","volume":"8","author":"Li","year":"2022","journal-title":"Chronic Dis Transl Med"},{"issue":"3","key":"2026031619574779200_dgaf681-B50","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s12020-018-1709-y","article-title":"Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's","volume":"62","author":"Hirsch","year":"2018","journal-title":"Endocrine"},{"issue":"8","key":"2026031619574779200_dgaf681-B51","doi-asserted-by":"crossref","first-page":"e13114","DOI":"10.1111\/jne.13114","article-title":"Clinical presentation and etiology of Cushing's syndrome: data from ERCUSYN","volume":"34","author":"Valassi","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2026031619574779200_dgaf681-B52","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol"},{"key":"2026031619574779200_dgaf681-B53","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2147\/TCRM.S37314","article-title":"Clinical use of pasireotide for Cushing's disease in adults","volume":"11","author":"Boscaro","year":"2015","journal-title":"TCRM"},{"issue":"6","key":"2026031619574779200_dgaf681-B54","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2174\/1570161115666170201105425","article-title":"Pathophysiology of diabetic dyslipidaemia","volume":"15","author":"Filippatos","year":"2017","journal-title":"CVP"},{"issue":"1","key":"2026031619574779200_dgaf681-B55","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026031619574779200_dgaf681-B56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fendo.2016.00042","article-title":"ACTH regulation of adrenal SR-B1","volume":"7","author":"Shen","year":"2016","journal-title":"Front Endocrinol"},{"issue":"6","key":"2026031619574779200_dgaf681-B57","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1194\/jlr.P033449","article-title":"High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C","volume":"54","author":"Bochem","year":"2013","journal-title":"J Lipid Res"},{"issue":"5","key":"2026031619574779200_dgaf681-B58","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.2011-2813","article-title":"Impact of mifepristone, a glucocorticoid\/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function","volume":"97","author":"Page","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026031619574779200_dgaf681-B59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11102-022-01227-x","article-title":"Glucocorticoid receptor blockers","volume":"25","author":"Molitch","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2026031619574779200_dgaf681-B60","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1507\/endocrj.43.645","article-title":"Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM: shared features with metabolic syndrome X and NIDDM","volume":"43","author":"Friedman","year":"1996","journal-title":"Endocr J"},{"issue":"3","key":"2026031619574779200_dgaf681-B61","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s12020-017-1370-x","article-title":"Cushing's syndrome: a model for sarcopenic obesity","volume":"57","author":"Drey","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"2026031619574779200_dgaf681-B62","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/cen.14568","article-title":"Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL","volume":"95","author":"Martel-Duguech","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026031619574779200_dgaf681-B63","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026031619574779200_dgaf681-B64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/ijem.ijem_260_23","article-title":"Efficacy and safety of osilodrostat in managing Cushing's syndrome: a systematic review and meta-analysis","volume":"28","author":"Nagendra","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"issue":"8","key":"2026031619574779200_dgaf681-B65","doi-asserted-by":"crossref","first-page":"e13113","DOI":"10.1111\/jne.13113","article-title":"Long-term morbidity and mortality in patients with Cushing's syndrome","volume":"34","author":"Braun","year":"2022","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2026031619574779200_dgaf681-B66","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1210\/clinem\/dgz136","article-title":"Time to diagnosis in Cushing's syndrome: a meta-analysis based on 5367 patients","volume":"105","author":"Rubinstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031619574779200_dgaf681-B67","doi-asserted-by":"crossref","first-page":"1187100","DOI":"10.3389\/fcvm.2023.1187100","article-title":"The role of glucocorticoids in increasing cardiovascular risk","volume":"10","author":"Deng","year":"2023","journal-title":"Front Cardiovasc Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf681\/66116773\/dgaf681.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/1187\/66116773\/dgaf681.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/1187\/66116773\/dgaf681.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:58:08Z","timestamp":1773705488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/4\/1187\/8402961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf681","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,23]]}}}